Kung Winston 4

What Happened

• Winston Kung, a director of Corbus Pharmaceuticals Holdings, received equity awards on May 19, 2026: 3,800 restricted stock units (RSUs) and a derivative award covering 12,300 shares. Both awards were granted at $0.00 (no cash paid) and will vest 100% on the one-year anniversary of the grant. The derivative award was made under the issuer’s 2024 Equity Compensation Plan.

Key Details

• Transaction date: May 19, 2026; Form 4 filed May 21, 2026 (timely — within the required filing period).
• Grants: 3,800 RSUs (settle into common shares upon vesting) and a 12,300-share derivative award (treated as an option/award).
• Price: $0.00 per share (compensation grant, not an open-market purchase).
• Vesting: Both awards vest 100% on the one-year anniversary from grant date.
• Footnotes: Filing notes these amounts include 8,600 unvested RSUs reported previously; the option award is under the 2024 Equity Compensation Plan and vests in one year.
• Shares owned after transaction: Not disclosed in this Form 4.

Context

• These are compensation grants (awards), not open-market purchases or sales. RSUs convert to shares only upon vesting; the derivative/option award similarly vests later and does not result in immediate shares or cash proceeds. Such grants are common executive/director compensation and do not by themselves indicate immediate buying or selling sentiment.